Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 468977)

  • 1. Calcitonin in nonthyroidal cancer.
    Schwartz KE; Wolfsen AR; Forster B; Odell WD
    J Clin Endocrinol Metab; 1979 Sep; 49(3):438-44. PubMed ID: 468977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The differential diagnosis of hypercalcitoninism].
    Dambacher MA; Born W; Heitz PU; Olah AJ; Tobler PH; Fischer JA
    Schweiz Med Wochenschr; 1981 Dec; 111(49):1897-901. PubMed ID: 7330642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcitonin in breast and lung cancer.
    Hillyard CJ; Coombes RC; Greenberg PB; Galante LS; MacIntyre I
    Clin Endocrinol (Oxf); 1976 Jan; 5(1):1-8. PubMed ID: 942890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and measurement of calcitonin precursors in serum of patients with malignant diseases.
    Ghillani PP; Motté P; Troalen F; Jullienne A; Gardet P; Le Chevalier T; Rougier P; Schlumberger M; Bohuon C; Bellet D
    Cancer Res; 1989 Dec; 49(23):6845-51. PubMed ID: 2555054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of plasma from patients with carcinoma on in vitro lymphocyte transformation.
    Silk M
    Cancer; 1967 Dec; 20(12):2088-9. PubMed ID: 5624179
    [No Abstract]   [Full Text] [Related]  

  • 6. [Association of serum tumor markers in solid neoplasms (CEA, ferritin, alpha 1-antitrypsin, parathormone and calcitonin)].
    Di Martino G; Iannucci F; Bizzarro A; Iacono G
    Boll Ist Sieroter Milan; 1982; 61(5):411-22. PubMed ID: 6985416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue-type plasminogen activator-induced fibrinolysis is enhanced in patients with breast, lung, pancreas and colon cancer.
    Nielsen VG; Matika RW; Ley ML; Waer AL; Gharagozloo F; Kim S; Nfonsam VN; Ong ES; Jie T; Warneke JA; Steinbrenner EB
    Blood Coagul Fibrinolysis; 2014 Apr; 25(3):248-53. PubMed ID: 24674880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcitonin immunoreactivity and hypercalcitoninemia in two patients with sporadic, nonfamilial, gastroenteropancreatic neuroendocrine tumors.
    McLeod MK; Vinik AI
    Surgery; 1992 May; 111(5):484-8. PubMed ID: 1350867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency and relevance of elevated calcitonin levels in patients with neoplastic and nonneoplastic thyroid disease and in healthy subjects.
    Karanikas G; Moameni A; Poetzi C; Zettinig G; Kaserer K; Bieglmayer C; Niederle B; Dudczak R; Pirich C
    J Clin Endocrinol Metab; 2004 Feb; 89(2):515-9. PubMed ID: 14764755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma calcitonin as a marker of disease activity in patients with small cell carcinoma of the lung.
    Wallach SR; Royston I; Taetle R; Wohl H; Deftos LJ
    J Clin Endocrinol Metab; 1981 Sep; 53(3):602-6. PubMed ID: 6267098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ectopic production of lipotropin by cancer.
    Odell WD; Wolfsen AR; Bachelot I; Hirose FM
    Am J Med; 1979 Apr; 66(4):631-8. PubMed ID: 433967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum levels of transforming growth factor alpha in gastrointestinal cancer patients.
    Moskal TL; Huang S; Ellis LM; Fritsche HA; Chakrabarty S
    Cancer Epidemiol Biomarkers Prev; 1995 Mar; 4(2):127-31. PubMed ID: 7742720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Monomeric plasmatic calcitonin and hypercalcemia in lung cancer patients].
    Coifman R; Weforte RV; Kasamatsu TS; Fukusima L; Santoro I; Jamnik S; Vieira JG; Castro ML
    Rev Assoc Med Bras (1992); 1997; 43(2):105-8. PubMed ID: 9336044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Calcitonin. III. Use of serum calcitonin as a tumor marker in breast and pulmonary neoplasms].
    Gadesberg CC; Nielsen HE; Olsen KJ; Hansen HH
    Ugeskr Laeger; 1979 Oct; 141(40):2744-6. PubMed ID: 531963
    [No Abstract]   [Full Text] [Related]  

  • 15. Production of immunoreactive corticotropin-releasing hormone in various neuroendocrine tumors.
    Tsuchihashi T; Yamaguchi K; Abe K; Yanaihara N; Saito S
    Jpn J Clin Oncol; 1992 Aug; 22(4):232-7. PubMed ID: 1359172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Radioimmunologic analysis of changes in the level of beta-2-microglobulin in cancer].
    Zubovskiĭ LG; Polevaia EB; Kirsanov AG; Shiriaev SV
    Med Radiol (Mosk); 1982 Aug; 27(8):50-3. PubMed ID: 6182439
    [No Abstract]   [Full Text] [Related]  

  • 17. A preliminary evaluation of calcitonin and PDN-21 as tumor markers for lung cancer. EORTC Lung Cancer Working Party.
    Body JJ; Dumon JC; Sculier JP; Dabouis G; Lacroix H; Libert P; Richez M; Bureau G; Mommen P; Raymakers N
    Henry Ford Hosp Med J; 1989; 37(3-4):190-3. PubMed ID: 2639133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma sialic acid alterations in neoplastic diseases.
    Dwivedi C; Dixit M; Kumar SS; Reddy H; Semenya KA; Hardy RE
    J Med; 1987; 18(5-6):323-32. PubMed ID: 3505259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypercalcitoninaemia in medullary carcinoma of the thyroid and other malignancies: value of calcitonin as tumour marker.
    Marrinan M; Skrabanek P; Moriarty M; McPartlin J; Powell D
    Horm Metab Res; 1982 Apr; 14(4):213-5. PubMed ID: 6282727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcitonin as a marker for bronchogenic cancer: a prospective study.
    Silva OL; Broder LE; Doppman JL; Snider RH; Moore CF; Cohen MH; Becker KL
    Cancer; 1979 Aug; 44(2):680-4. PubMed ID: 476577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.